The role of fibrin glue needs to be further investigated.”
“Objectives: Surgery for varicose veins is still the method of choice worldwide. When varicose veins require bilateral surgery, a single procedure often is
the preferred choice by the patient. Today, unilateral varicose vein surgery is frequently performed as an outpatient BAY 63-2521 research buy procedure, while in many institutions bilateral surgery is done as an in-hospital procedure.
Design: Retrospective comparative study.
Methods: Between 1 October 2004 and 31 October 2006, 433 patients underwent surgery for the great saphenous vein as in-patient procedure (303 unilateral and 130 bilateral), period 1. From 1 November 2006 until 31 December 2009, 825 patients had ambulatory great saphenous vein surgery (550 unilateral and 275 bilateral),
period 2. We have compared unilateral and bilateral varicose vein surgery (high ligation and stripping of the great saphenous vein) and in-hospital procedures with ambulatory surgery, with regard to postoperative complications, postoperative pain and midterm follow-up.
Results: Operation time and total length of stay in the institution following varicose vein surgery were significantly shorter for period 2 compared with period 1 for both unilateral and bilateral surgery, without other differences between the groups. There were few postoperative complications without differences between Aurora Kinase inhibitor periods, and between unilateral and bilateral surgery (wound infection 0.5%, haematoma requiring drainage 0.2%, transient paraesthesia 1.1%, superficial localised thrombophlebitis 0.6% SNX-5422 order and deep vein thrombosis in one unilaterally operated case only).
Conclusions: Bilateral varicose vein surgery can be safely performed as an outpatient procedure, without increased risk of postoperative
complications, increased postoperative discomfort or midterm adverse effects compared with unilateral surgery. (C) 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.”
“Twenty-nine actinobacterial strains were isolated from marine sponge Spongia officinalis and screened for antagonistic activity against various bacterial and fungal pathogens. The active antibiotic producer MAPS15 was identified as Streptomyces sp. using 16S rRNA phylogenetic analysis. The critical control factors were selected from Plackett-Burman (PB) factorial design and the bioprocess medium was optimized by central composite design (CCD) for the production of bioactive metabolite from Streptomyces sp. MAPS15. The maximum biomass and active compound production obtained with optimized medium was 6.13 g/L and 62.41 mg/L, respectively. The economical carbon source, paddy straw was applied for the enhanced production of bioactive compound. The purified active fraction was characterized and predicted as pyrrolidone derivative which showed broad spectrum of bioactivity towards indicator organisms. The predicted antimicrobial spectra suggested that the Streptomyces sp.